CVS Health (CVS) Tops Q2 EPS by 72c, Offers FY Guidance

CVS Health (NYSE: CVS) reported Q2 EPS of $2.64, $0.72 better than the analyst estimate of $1.92. Revenue for the quarter came in at $65.3 billion versus the consensus estimate of $64.18 billion.

GUIDANCE:

CVS Health sees FY2020 EPS of $7.14-$7.27, versus the consensus of $7.16.

• Raised GAAP diluted EPS guidance range to $5.59 to $5.72 from $5.47 to $5.60
• Raised Adjusted EPS (2) guidance range to $7.14 to $7.27 from $7.04 to $7.17
• Raised cash flow from operations guidance range to $11.0 billion to $11.5 billion from $10.5 billion to $11.0 billion

For earnings history and earnings-related data on CVS Health (CVS) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• CVS Pharmacy® expands GLP‑1 support to lower costs, improve access, and help patients stay on therapy
• Jefferies Reinstates Talen Energy (TLN) at Hold